Liver Function Tests (LFT) and Hepatic Enzymes

The clinical laboratory panel commonly referred to as "Liver Function Tests" (LFTs) is a composite biochemical battery that assesses three distinct pathophysiological domains of the hepatobiliary axis:

1. Hepatocellular Integrity and Necrosis: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).
2. Canalicular and Biliary Excretory Capacity (Cholestasis): Alkaline Phosphatase (ALP), Gamma-Glutamyl Transferase (GGT), and Total/Direct Bilirubin.
3. True Hepatic Synthetic Capacity: Serum Albumin and Prothrombin Time / International Normalized Ratio (INR).

Understanding the cellular localization of these enzymes is the foundation of clinical interpretation:

• Alanine Aminotransferase (ALT): Located almost exclusively in the cytosol of hepatocytes. Because extra-hepatic concentrations are negligible, ALT is the most specific circulating enzymatic biomarker for hepatocellular parenchymal injury.
• Aspartate Aminotransferase (AST): Exists as two distinct isoenzymes: cytosolic (cAST, ~20%) and mitochondrial (mAST, ~80%). AST is widely distributed not only in liver tissue, but also in cardiac myocardium, skeletal muscle, kidneys, brain, pancreas, and erythrocytes. Acute muscle injury (rhabdomyolysis, intense weightlifting, myocardial infarction) or in vitro specimen hemolysis regularly elevates serum AST independently of liver disease.
• Alkaline Phosphatase (ALP): A zinc metalloenzyme anchored via glycosylphosphatidylinositol to the canalicular and microvillar membranes of hepatocytes and bile duct cholangiocytes. ALP is also heavily expressed in osteoblasts (bone), placental syncytiotrophoblasts (pregnancy), and intestinal brush border mucosa. In cholestasis, bile acids accumulate and stimulate de novo canalicular synthesis and membrane cleavage of ALP into the bloodstream.
• Gamma-Glutamyl Transferase (GGT): Membrane-bound enzyme found in hepatobiliary cholangiocytes, renal tubular brush borders, and pancreas, but absent in bone tissue. Thus, GGT serves as the essential adjudicator to confirm whether an elevated ALP originates from the biliary tract.
• Bilirubin Metabolism: Erythrocyte breakdown yields biliverdin, which is reduced to water-insoluble unconjugated (indirect) bilirubin. In hepatocytes, it is bound to ligandin and conjugated with glucuronic acid by the enzyme uridine diphosphate glucuronosyltransferase (UGT1A1) to form water-soluble conjugated (direct) bilirubin, which is actively excreted into bile canaliculi across the MRP2 transporter.

• Hemolysis Interference: Hemolyzed serum specimens falsely elevate AST because erythrocytes contain approximately 40 times higher AST concentrations than plasma. Hemolysis also causes optical interference with colorimetric diazo bilirubin assays.
• Patient Fasting Status: Routine LFTs do not strictly require fasting, but a high-fat meal can elevate circulating alkaline phosphatase of intestinal origin in individuals with blood groups O and B. Bilirubin in Gilbert syndrome rises significantly with prolonged fasting (> 18–24 hours).
• Vigorous Physical Exercise: Intense resistance training, marathon running, or unaccustomed weightlifting causes transient rhabdomyolysis that raises AST (often > 100–300 U/L) and ALT with a high AST/ALT ratio, easily mistaken for acute liver damage. Always check serum creatine kinase (CK) in athletic individuals with asymptomatic transaminitis.
• Specimen Light Exposure: Bilirubin is highly photolabile; exposure of serum separator tubes to ambient fluorescent light or sunlight causes photo-isomerization and lowers measured total bilirubin by up to 30% to 50% per hour. Tubes must be protected from light if analysis is delayed.

Ordering an LFT panel is clinically indicated in:

1. Clinical Symptoms of Hepatobiliary Disease: Jaundice, dark tea-colored urine, pale acholic stools, right upper quadrant pain, pruritus, ascites, or hepatic encephalopathy.
2. Monitoring Hepatotoxic Medications: Statins, antitubercular therapy (isoniazid, rifampin, pyrazinamide), anti-epileptics (valproate, carbamazepine), methotrexate, biologics, chemotherapy, and acetaminophen overdose.
3. Screening for Chronic Viral Hepatitis: Screening for Hepatitis B (HBsAg) and Hepatitis C (anti-HCV) in at-risk populations.
4. Cardiometabolic Risk Stratification: Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD / MASH) in patients with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome.
5. Pre-operative Surgical Assessment: Evaluating hepatic synthetic reserve prior to major abdominal, cardiac, or hepatic resection surgery.

┌─────────────────────────────────────────────────────────────┐
│          5-STEP SYSTEMATIC LIVER PANEL INTERPRETATION       │
├─────────────────────────────────────────────────────────────┤
│ Step 1: Characterize the Primary Pattern via R-Ratio        │
│         R = (ALT / ALT ULN) / (ALP / ALP ULN)               │
│         ├─ R >= 5.0: Hepatocellular Pattern                 │
│         ├─ R <= 2.0: Cholestatic Pattern                    │
│         └─ R 2.0 - 5.0: Mixed Pattern                       │
├─────────────────────────────────────────────────────────────┤
│ Step 2: If Hepatocellular (Elevated ALT/AST):               │
│         Assess the Magnitude of Transaminase Elevation:     │
│         ├─ Massive (> 1,000 - 10,000 U/L): Shock liver      │
│         │  (ischemic), Acetaminophen toxicity, Acute viral  │
│         │  hepatitis (A/B/E), or Autoimmune hepatitis       │
│         ├─ Moderate (200 - 1,000 U/L): Acute biliary        │
│         │  obstruction (transient spike), DILI, Severe MASH │
│         └─ Mild (< 200 U/L): Chronic viral hep B/C, MASH,   │
│            Alcohol, Hemochromatosis, Celiac, Thyroid        │
│         Calculate De Ritis Ratio (AST / ALT):               │
│         ├─ AST/ALT >= 2.0: Alcohol-associated liver disease │
│         └─ AST/ALT > 1.0 in viral/MASH: Advanced cirrhosis  │
├─────────────────────────────────────────────────────────────┤
│ Step 3: If Cholestatic (Elevated ALP):                      │
│         Adjudicate Hepatic Origin via GGT:                  │
│         ├─ GGT Elevated: Biliary / Hepatic etiology         │
│         │  Order right upper quadrant ultrasound (RUQ US)   │
│         │  ├─ Dilated Ducts: Extrahepatic obstruction       │
│         │  │  (Choledocholithiasis, cholangiocarcinoma)     │
│         │  └─ Non-Dilated Ducts: Intrahepatic cholestasis   │
│         │     (PBC: check AMA; PSC: check MRCP; DILI, sepsis│
│         └─ GGT Normal: Bone etiology (Paget, fracture, tumor)│
├─────────────────────────────────────────────────────────────┤
│ Step 4: Fractionate Bilirubin Elevation                     │
│         ├─ Indirect (Unconjugated) > 80%: Hemolysis (check  │
│         │  CBC, retics, LDH, haptoglobin) or Gilbert syn-   │
│         │  drome (normal enzymes and blood counts)          │
│         └─ Direct (Conjugated) > 20 - 35%: Hepatic paren-   │
│            chymal disease or biliary tract obstruction      │
├─────────────────────────────────────────────────────────────┤
│ Step 5: Evaluate True Synthetic Liver Function              │
│         Assess Prothrombin Time (PT/INR) and Albumin:       │
│         ├─ Elevated INR: Acute liver failure or cirrhosis   │
│         │  (Administer parenteral Vit K to rule out mal-    │
│         │  absorption before diagnosing liver failure)      │
│         └─ Low Albumin: Chronic liver disease or systemic   │
│            malnutrition / nephrotic proteinuria.            │
└─────────────────────────────────────────────────────────────┘

• Amoxicillin-Clavulanate (Augmentin): The leading cause of idiosyncratic drug-induced liver injury (DILI) in Western countries. Classically produces a delayed cholestatic or mixed hepatitis appearing 2 to 6 weeks after antibiotic completion.
• Acetaminophen (Paracetamol): Generates the toxic reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which depletes hepatocyte glutathione and produces centrilobular necrosis with transaminases often exceeding 10,000 U/L. Administer intravenous N-acetylcysteine (NAC) based on the Rumack-Matthew nomogram.
• Statins (HMG-CoA Reductase Inhibitors): Frequently induce asymptomatic, transient elevations of transaminases in 1% to 3% of patients. In the absence of clinical jaundice or bilirubin elevation, statin therapy does not cause progressive liver failure and does not require discontinuation unless ALT persistently exceeds 3× ULN.
• Pyridoxal-5'-Phosphate Deficiency (Chronic Alcoholism, Uremia): Coenzyme required for ALT and AST activity. Suppression of ALT synthesis is far more profound than AST, creating a high AST/ALT ratio even in non-alcoholic uremic states.

1. The "Normal LFTs in Cirrhosis" Paradox: Patients with end-stage burnt-out cirrhosis may have completely normal ALT, AST, and ALP because so few functional hepatocytes remain to release intracellular enzymes. True functional markers (INR, albumin, platelets reflecting portal hypertension) unmask the disease.
2. Attributing Elevated ALP to the Liver Without Checking GGT: In an elderly patient with isolated ALP elevation, assuming gallbladder disease without checking GGT or bone isoenzymes frequently leads to unnecessary biliary imaging when the actual etiology is Paget's disease of bone or osteoblastic bone metastases.
3. The "Transient Transaminase Spike" in Choledocholithiasis: Passage of a gallstone through the ampulla of Vater can trigger an acute, fleeting spike in ALT and AST to > 500–1,000 U/L within hours due to acute intraductal pressure backflow, mimicking acute viral or ischemic hepatitis. Transaminases fall dramatically within 24 to 48 hours as the typical cholestatic ALP elevation emerges.

• The De Ritis Ratio Rule: If AST/ALT ≥ 2.0 → Think Alcohol. If AST/ALT > 1.0 in chronic Hep C or MASH → Think Cirrhosis (damaged liver can no longer clear sinusoidal AST). If ALT > AST → Think uncomplicated viral hepatitis or early steatohepatitis.
• True Liver Synthetic Function: Always answer Prothrombin Time / INR as the most acute marker of hepatic synthesis (Factor VII half-life is only 4 to 6 hours). Albumin has a half-life of 20 days and only reflects chronic insufficiency.
• Gilbert vs Crigler-Najjar: Both cause unconjugated hyperbilirubinemia due to UGT1A1 deficiency. Gilbert = benign promoter defect (TA duplication), bilirubin < 4–5 mg/dL, completely normal lifespan. Crigler-Najjar Type 1 = complete absence of UGT1A1, severe kernicterus, fatal without liver transplantation.
• The R-Factor Calculation: In acute DILI, calculate R = (ALT/ULN) / (ALP/ULN). If R ≥ 5 → Hepatocellular (e.g. isoniazid); if R ≤ 2 → Cholestatic (e.g. amoxicillin-clavulanate, estrogen); if 2 < R < 5 → Mixed.

• Complete Blood Count (CBC): Evaluates splenomegaly-induced thrombocytopenia in portal hypertension (Complete Blood Count).
• Coagulation Profile (PT/INR): Crucial immediate assessment of acute and chronic liver synthetic function (Coagulation Profile).
• Renal Function Tests & Electrolytes: Assesses hepatorenal syndrome and hyponatremia in advanced cirrhosis (Renal Function Tests).
• Right Upper Quadrant (RUQ) Ultrasound: First-line imaging to detect biliary dilatation, cholelithiasis, hepatic steatosis, and cirrhosis.
• Viral Hepatitis Serology Panel: Assesses HBsAg, anti-HBc IgM, anti-HCV, and anti-HAV IgM in acute or chronic transaminitis.